UA83065C2 - Method for treating mesothelioma with the use of hdac inhibitors - suberoylanilide hydroxamic acid (saha) - Google Patents
Method for treating mesothelioma with the use of hdac inhibitors - suberoylanilide hydroxamic acid (saha)Info
- Publication number
- UA83065C2 UA83065C2 UAA200603184A UAA200603184A UA83065C2 UA 83065 C2 UA83065 C2 UA 83065C2 UA A200603184 A UAA200603184 A UA A200603184A UA A200603184 A UAA200603184 A UA A200603184A UA 83065 C2 UA83065 C2 UA 83065C2
- Authority
- UA
- Ukraine
- Prior art keywords
- hdac inhibitors
- saha
- pharmaceutical compositions
- present
- hydroxamic acid
- Prior art date
Links
- 206010027406 Mesothelioma Diseases 0.000 title abstract 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229960000237 vorinostat Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More specifically, 5 the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of D pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily T dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83065C2 true UA83065C2 (en) | 2008-06-10 |
Family
ID=37444418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200603184A UA83065C2 (en) | 2003-08-26 | 2004-08-26 | Method for treating mesothelioma with the use of hdac inhibitors - suberoylanilide hydroxamic acid (saha) |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1870985B (en) |
| CY (1) | CY1110659T1 (en) |
| IS (1) | IS8357A (en) |
| UA (1) | UA83065C2 (en) |
| ZA (1) | ZA200601589B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009305214B2 (en) | 2008-10-15 | 2015-06-25 | Generics [Uk] Limited | Process for the preparation of vorinostat |
| CN103159646B (en) * | 2013-03-19 | 2014-10-22 | 广东药学院 | Hydroxamic acid compound, and preparation method and application thereof |
| CN104292134B (en) * | 2014-10-10 | 2016-06-22 | 广东药学院 | Hydroxamic acid compound and its preparation method and application |
| CN109705057B (en) * | 2017-10-25 | 2023-05-30 | 成都先导药物开发股份有限公司 | Histone deacetylase inhibitor and its preparation method and use |
| CN111973590A (en) * | 2020-07-06 | 2020-11-24 | 江苏省人民医院（南京医科大学第一附属医院） | Application of novel HDAC inhibitor LAQ824 in medicine for treating diffuse large B cell lymphoma |
-
2004
- 2004-08-26 CN CN2004800313068A patent/CN1870985B/en not_active Expired - Fee Related
- 2004-08-26 UA UAA200603184A patent/UA83065C2/en unknown
-
2006
- 2006-02-23 ZA ZA200601589A patent/ZA200601589B/en unknown
- 2006-03-17 IS IS8357A patent/IS8357A/en unknown
-
2010
- 2010-06-28 CY CY20101100592T patent/CY1110659T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS8357A (en) | 2006-03-17 |
| ZA200601589B (en) | 2007-05-30 |
| CN1870985B (en) | 2011-11-30 |
| CY1110659T1 (en) | 2015-06-10 |
| CN1870985A (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1663194T1 (en) | Use of SAHA for treating mesothelioma | |
| WO2005039498A3 (en) | Methods of treating cancer with hdac inhibitors | |
| WO2003075839A3 (en) | Methods of inducing terminal differentiation | |
| TW200510375A (en) | New compounds | |
| EP1961748A3 (en) | 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | |
| MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| DE602005021770D1 (en) | INDOLE-1-YL-ACETIC DERIVATIVES | |
| IL179718A0 (en) | Pharmaceutical composition containing irbesartan | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| UA86441C2 (en) | (2-hydroxyethyl)trimethylammonium thiooctate (choline thioctate), having hepatoprotective, hypoamoniemic and detoxic action, method for production thereof and pharmaceutical compositions based on it | |
| UA96794C2 (en) | Glucocorticoides, method of use thereof, treatment method and pharmaceutical formulation based thereon | |
| TW200639159A (en) | Treatment of pain | |
| CY1110659T1 (en) | USE TOY SAHA FOR MEDICAL THERAPEUTIC ADMINISTRATION | |
| UA90893C2 (en) | Oral dosage forms of gemcitabine derivatives | |
| SI1730144T1 (en) | Substituted 1,4,8-triazaspiro 4.5 decan-2-one compounds | |
| MXPA04004907A (en) | Acetaminophen compositions. | |
| AU2001246388A1 (en) | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine | |
| TW200505916A (en) | 7-azaindoles and the use thereof as therapeutic agents | |
| TW200503693A (en) | 4-, 6- or 7-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents | |
| MXPA05007253A (en) | Novel anticonvulsant derivative salts. | |
| TW200509902A (en) | Pharmaceutical formulation for the treatment of overactive bladder | |
| WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
| UA54880C2 (en) | (s)-2-amino-5-guanidinopentanoic acid (s)-2-aminoglutarate (l-arginine l-glutamate) possessing hepatoprotecting, hypoammoniemic, and detoxifying activity, method for its synthesis and pharmaceutical composition containing this substance | |
| UA95650C2 (en) | Biaryl ether urea compounds, pharmaceutical composition and method for the treatment diseases associated with fatty acid amide hydrolase activity |